Cagrilintide 5 mg single-compound vial

Buy Cagrilintide 5 mg for laboratory research, supplied as lyophilized powder in one boxed 3 mL vial.

Cagrilintide is a modified amylin analog.

Compare sizes and formulations

The Cagrilintide 10 mg listing offers a different labeled amount of the same named compound. Choose the amount required for the planned laboratory work and check the records attached to that presentation.

The Cagrilintide + GLP1-S 10 mg blend is a separate formulation containing 5 mg of each listed component. Its 10 mg total does not mean 10 mg of Cagrilintide. A single-compound vial and a premixed blend support different experimental comparisons.

How the analog differs from native amylin

Native amylin’s tendency to form amyloid fibrils was a design challenge addressed by Kruse and colleagues in the Cagrilintide development study. The researchers used structure-activity comparisons to develop a lipidated analog.

Lipidation is a chemical modification of the peptide, not a second ingredient physically blended into the vial. Cagrilintide therefore differs structurally from unmodified amylin. The development paper concerns the defined construct studied by its authors; it does not establish a shelf life or preparation protocol for this commercial powder.

When selecting a reference material, compare the complete molecular form required by the method, including modifications and any specified counterion. A broad label such as “amylin analog” is not enough to establish that two materials are equivalent.

Certificate of analysis and supporting documents

Open COA & Documents and match the product and lot. Review identity, chromatographic purity and measured content separately. A purity percentage is not the same measurement as milligrams per vial.

Use the available product files for handling information applicable to the supplied material. The 3 mL figure is container capacity, not a liquid fill volume or a prescribed preparation volume.